布地奈德(Budesonide) - 药物靶点：GR_在研适应症：免疫球蛋白a肾病，嗜酸粒细胞性食管炎，溃疡性结肠炎_专利_临床

概要

基本信息

简介布地奈德是一种作为激动剂与糖皮质激素受体（GR）结合能力强的小分子药物，早在1981年就获批上市，至今已有40多年的历史。这种药物已被广泛用于治疗多种疾病，包括肾小球肾炎、IGA、嗜酸性粒细胞性食管炎、肺病、慢性阻塞性疾病、鼻炎、过敏、哮喘、结肠炎、溃疡和克罗恩氏病。其显着功效被认为源于其调节免疫系统的能力，从而减少炎症和防止组织损伤。

药物类型

小分子化药

别名

Budenofalk Granules、Budesolv、Budesonide gastro-resistant granules

+ [72]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

免疫系统疾病感染消化系统疾病+ [4]

在研适应症

免疫球蛋白a肾病嗜酸粒细胞性食管炎溃疡性结肠炎+ [10]

非在研适应症

急性哮喘急性移植物抗宿主病过敏+ [18]

原研机构

阿斯利康制药有限公司

在研机构

Zeria Pharmaceutical Co., Ltd.

STADA Arzneimittel AGEverest Medicines (Singapore) Pte Ltd.

+ [28]

非在研机构

Takeda Pharmaceutical Co., Ltd.云屹药业（上海）有限公司

Pearl Therapeutics, Inc.

+ [7]

权益机构

Kissei Pharmaceutical Co., Ltd.Ferring Holding SA

Calliditas Therapeutics AB

+ [24]

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、突破性疗法 (中国)、附条件批准 (中国)、孤儿药 (韩国)、孤儿药 (澳大利亚)、附条件批准 (欧盟)、附条件批准 (英国)、快速通道 (韩国)、加速批准 (中国台湾)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C25H34O6

InChIKeyVOVIALXJUBGFJZ-KWVAZRHASA-N

CAS号51333-22-3

关联

639

项与布地奈德相关的临床试验

NCT06860542

/ Not yet recruiting临床2期IIT

Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis

The introduction of immune checkpoint inhibitors (immunotherapy) that stimulate our immune system to recognize and attack cancer cells has been one of the most exciting advances in oncology over the last decade. These medications are now employed across almost half of cancer types and settings, however they come with a cost. In some patients, instead of attacking cancer cells alone, the stimulated immune system damages healthy tissues (immune related adverse events), with one of the most severe and potentially deadly such complications being immune attack on the lungs, or checkpoint inhibitor pneumonitis (CIP). When treated promptly with oral or intravenous steroids, acute CIP improves in many cases, however for approximately one-fifth of patients the lung inflammation is difficult to control, resulting in recurrent shortness of breath, the need for extended courses of oral or intravenous steroids, impacting quality of life and cancer therapy decisions. The goal of the trial is to assess whether use of inhaled steroids, a type of medication commonly used in asthma patients, for one year after a first diagnosis of CIP may help the lung inflammation resolve and not return, without the repeated use of oral or intravenous medications that carry more side effects.

开始日期2025-09-01

申办/合作机构

AHS Cancer Control Alberta

NCT06855043

/ Not yet recruiting临床2期IIT

Pilot Study of Late Surfactant Therapy With Budesonide for Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Infants

This clinical trial is being done to evaluate the clinical response and safety of late surfactant treatment with budesonide in extremely preterm infants requiring mechanical ventilation at 7-14 days of age.
The main questions it aims to answer are:
* Do the combined drugs improve the respiratory severity score (RSS)
* Is the combination safe
Participants will receive three doses of the study drug.

开始日期2025-07-01

申办/合作机构

University of Wisconsin Madison

CTR20252038

/ Active, not recruitingN/A

布地奈德肠溶胶囊餐后人体生物等效性研究

研究餐后状态下单次口服受试制剂布地奈德肠溶胶囊（4 mg）与参比制剂布地奈德肠溶胶囊（TARPEYO®，4 mg）在健康成年受试者体内的药代动力学，评价两种制剂的生物等效性和安全性。

开始日期2025-06-19

申办/合作机构

齐鲁制药有限公司

100 项与布地奈德相关的临床结果

登录后查看更多信息

100 项与布地奈德相关的转化医学

登录后查看更多信息

100 项与布地奈德相关的专利（医药）

登录后查看更多信息

10,533

项与布地奈德相关的文献（医药）

2025-12-31·Journal of Pharmaceutical Policy and Practice

Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation

Article

作者: Yu, Shule ; Wang, Menglei ; Yang, Qingqing ; Guo, Wei ; Lu, Wei ; Zheng, Fangfang ; Chen, Hongdou ; Wu, Huanhuan ; Li, Wei

Background:

The maintenance medicines for chronic obstructive pulmonary disease (COPD) include inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABA). Budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are two representative drugs for prefixed ICS/LAMA/LABA association in a single inhaler and have shown comparable efficacy and safety with other ICS/LAMA/LABA open combination therapies in patients with moderate-to-very severe COPD. This study aimed to investigate the availability, price, affordability, and utilisation of single-inhaler triple medicines for COPD in China.

Methods:

Quarterly data about the use of BUD/GLY/FOR and FF/UMEC/VI from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. We used the adjusted World Health Organization and Health Action International methodology to calculate the availability and affordability of the two investigated medicines in 596 tertiary general hospitals and 299 secondary general hospitals in 31 provincial administrative regions in China.

Results:

The availability and consumption of BUD/GLY/FOR were significantly higher than those of FF/UMEC/VI during the study period. At the end of 2022, the availability of BUD/GLY/FOR and FF/UMEC/VI in tertiary general hospitals was 69.80% and 52.01% respectively, while in secondary general hospitals, it was 52.51% and 28.76% respectively. Both medications were equally affordable at 1.3 days of the minimum wage after reimbursement in 2022. In the first quarter of 2021, with the inclusion of both drugs in the Medicare catalog, their DDDc decreased significantly, which was accompanied by notable improvements in their availability, affordability and consumption.

Conclusions:

The overall accessibility and consumption of BUD/GLY/FOR and FF/UMEC/VI were improved in China from 2020 to 2022. The implementation of the national drug price negotiation policy reduces the cost of drugs in China and plays an important role in improving the availability of the investigated drugs.

2025-12-01·LUNG

Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study

Article

作者: Soendergaard, Marianne Baastrup ; Hansen, Susanne ; Johnsen, Claus Rikard ; Hjortdahl, Frederikke ; Walls, Anne Byriel ; Bonnesen, Barbara ; Håkansson, Kjell Erik Julius ; Bjerrum, Anne-Sofie ; Hilberg, Ole ; Ulrik, Charlotte Suppli ; von Bülow, Anna ; Johansson, Sofie Lock ; Porsbjerg, Celeste ; Rasmussen, Linda Makowska ; Schmid, Johannes Martin

Abstract:

Background:

In severe asthma, intensive (“supratherapeutic”) doses of inhaled corticosteroids (ICS) are often used. The prevalence of supratherapeutic ICS use and its impact on corticosteroid-related comorbidities is poorly understood. We aimed to describe the prevalence of supratherapeutic ICS use in severe asthma, its relation to corticosteroid-related comorbidities, and changes in prescribed and redeemed ICS dose after 12 months of biologic therapy.

Methods:

Patients from the nationwide Danish Severe Asthma Register (DSAR) receiving biologic therapy > 12 months were included. Supratherapeutic doses were defined as > 1600 µg budesonide daily. Baseline characteristics, comorbidity burden, and change in ICS use after 12 months of biologic therapy was stratified according to ICS use at baseline.

Results:

We included 652 patients in our analyses and 156 (24%) were supratherapeutic ICS users prior to initiation of biologic therapy. Supratherapeutic ICS users had a higher baseline prevalence of cataracts at 14 vs 8.1%; p = 0.025. No differences in other corticosteroid-related comorbidities were observed.No change in prevalence of prescribed supratherapeutic ICS was seen after 12 months of biologic therapy. However, a reduction in ICS adherence among supratherapeutic users was observed with 72% of patients demonstrating > 80% adherence at 12 months, compared to 83% at baseline (p < 0.001).

Conclusion:

Supratherapeutic doses of ICS were used by almost one-fourth of the patients prior to initiation of biologic therapy and were associated with a higher prevalence of cataracts. Physician-driven ICS reduction was rare, yet supratherapeutic ICS users were found to self-regulate ICS therapy when treated with biologic therapy.

2025-12-01·LUNG

Efficacy of Nebulized Budesonide and Systemic Corticosteroids During Hospitalization on All-Cause Mortality in AECOPD Patients: A Real-World Study

Article

作者: Meng, Weiwei ; Chen, Yan ; Zhao, Rui ; Zeng, Huihui ; Wu, Jiankang ; Wang, Jiayu ; He, Xue ; Zhao, Zhiqi ; Cui, Yanan ; Xiong, Ruoyan

BACKGROUND:

Guidelines specify steroids as therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, the duration of survival benefit associated with steroids and the optimal dosage of nebulized budesonide (NB) during hospitalization remain unclear.

METHODS:

We conducted a retrospective study of hospitalized AECOPD patients. The primary endpoint was all-cause mortality after discharge. Cox regression analysis was used to determine the impact of steroid therapy on survival.

RESULTS:

Wilcoxon analysis showed the positive impact of systemic corticosteroids (SCs) therapy on survival during the early stage of follow-up (P = 0.038). NB therapy was associated with a significantly reduced risk of death within six months after discharge (adjusted Hazard ratio (HR), 0.36; 95% confidence interval (CI) 0.15-0.88). Subgroup analysis suggested that fewer than two AEs in the previous year (adjusted HR 0.05; 95% CI 0.01-0.38), age > = 65 years (adjusted HR 0.31; 95% CI 0.11-0.90), body mass index (BMI) < 25 kg/m² (adjusted HR 0.33; 95% CI 0.12-0.92), and smoking index > 40 packets/year (adjusted HR 0.17; 95% CI 0.04-0.79) were involved in this association. Finally, treatment with a total dose of NB < = 60 mg during hospitalization reduced six-month mortality compared to treatment without steroids (adjusted HR 0.39; 95% CI 0.17-0.92), but not the total dose of NB > 60 mg.

CONCLUSIONS:

NB therapy for hospitalized AECOPD patients significantly reduced six-month mortality. Subgroup analysis showed that certain populations benefited more from NB therapy, and < = 60 mg NB might be suitable treatment for hospitalized AECOPD patients.

953

项与布地奈德相关的新闻（医药）

2025-07-18

·丁香园

刚进医保半年，这款「救命药」全国断供了

最近，社交平台上有不少人发帖称：布地奈德肠溶胶囊断货了。随后，江苏、天津、浙江、广东等地多位肾内科医生也证实了这个消息，有医生表示：「断货将近一个月了，也不知道什么原因。」图源：社交媒体这款被称为 IgA 肾病患者「救命药」的全球首款对因药，国内获批刚过一年半，为什么突然断货了？全球首款「救命药」，今年 5 月刚获「完全批准」中国是全球原发性肾小球疾病发病率最高的国家，原发性肾小球疾病是一类疾病，其中 IgA 肾病约占 35～50%，我国共约 500 万患者，每年新增确诊超过 10 万。[1]不同地区、不同种族的 IgA 肾病存在明显差异，我国的 IgA 肾病患者，病理改变更严重、疾病进展速度也更快。[2]此前，国内针对 IgA 肾病的治疗，主要以支持性治疗和全身免疫抑制剂为主，缺乏对因治疗。[2]2023 年 11 月 24 日，云顶新耀公司宣布，布地奈德肠溶胶囊获得国家药监局附条件批准上市，是全球首个且唯一一个 IgA 肾病的对因治疗药物。[2]图源：参考资料 1、3在此之前，布地奈德肠溶胶囊已经获美国 FDA 和欧盟批准。今年 5 月 7 日，布地奈德肠溶胶囊正式获得国家药监局同意，由附条件批准转为完全批准，取消了对蛋白尿水平的限制。[1]支持其获批的 NefIgArd III 期全球临床试验显示，经过 9 个月的治疗、停药观察 15 个月后，布地奈德肠溶胶囊可使患者的肾功能衰退减少 66%，同时使蛋白尿下降 43%，无镜下血尿的患者比例，从基线的 26.9% 增至 57.7%。[4]图源：参考资料 4「这个药在临床上效果还是可以的，副作用也比较少。」天津市泰达医院肾内科主任医师李青教授提到，作为唯一对因药，刚上市时布地奈德肠溶胶囊的价格不算便宜，每月需 2 万元左右。「并不是所有 IgA 肾病患者都能负担，所以一开始临床用得也不多。」不过这种情况持续时间并不算长，国内获批一年多后，布地奈德肠溶胶囊进医保了。获批一年后进医保，需求增加产能没跟上2024 年 11 月 28 日，《国家基本医疗保险、工伤保险和生育保险药品目录（2024 年）》发布，布地奈德肠溶胶囊赫然在列。[5]而随着最新版医保目录的正式实施，今年 1 月 1 日起，布地奈德肠溶胶囊开始在北京、上海等各省市执行医保报销，患者可在定点医疗机构或定点药店购药，并享受医保报销价格。[6]图源：参考资料 5随着价格「跳水」，越来越多患者选择使用布地奈德肠溶胶囊，市场需求明显上涨。「进医保前，2 万一个月，很多人望而却步，进医保后，现在大概每个月 5000 左右，医保报销后自费 1000 多，不少患者咬咬牙就用了，这个需求的增加，临床上感觉还是蛮明显的。」李青表示。图源：社交媒体需求增加，是所有药企都喜闻乐见的趋势，但为什么进医保才半年多，突然就断货了？其中缘由也不复杂：产能没跟上。其实云顶新耀也不是没有提前布局，据其内部工作人员透露，今年 2 月公司已经向国家药监局药品审评中心提交了扩大产能的申请，但目前仍在等待审评，暂无下文。布地奈德肠溶胶囊的说明书显示，其生产企业为美国公司 Patheon Pharmaceuticals Inc [7]。业内人士分析认为，2 月份的扩大产能申请，应该指的是扩大国内产能。至于什么时候能恢复稳定供货，云顶新耀工作人员表示，目前暂无确切消息。临床医生：断货对疗程内患者影响较大关于本次布地奈德肠溶胶囊突然断货的原因，一些临床医生有着不同看法。江苏某三甲医院肾内科主任郑可（化名）就提到，其实对于整个肾内科来讲，真正选择使用布地奈德肠溶胶囊的患者比例并不高。「我接诊的患者里只有 3～5 位。」所以郑可认为，厂家应该不至于对新增的需求完全没有预判和应对能力，如此突然的断货，让他不能理解。但断货原因并不是临床医生关注的重点，断货给患者带来的实实在在的影响才是医生们头疼的事。临床上，布地奈德肠溶胶囊的使用方式为固定疗程 9 个月，每日口服一次，剂量 16mg；完成 9 个月疗程或提前终止治疗时，需减少剂量至 8mg，每日一次，持续 2 周。[8]IgA 肾病治疗方案总结图源：丁香园肾脏时间因此不少医生表示，突然断货对于那些在疗程内，尤其是疗程中期的患者来说影响较大。「这个新药，不少患者还是抱有较高期待的，现在断货了，他们都比较焦虑。」郑可表示，为了避免直接停药造成更大的不良影响，他一般提议患者更换为普通的糖皮质激素，「但总归不是一模一样的药，有些患者不接受换药，只能逐步减量试试，或者就是想办法找找哪里还有库存了。」李青也提到，是一位外地患者询问他，他才知道原来布地奈德肠溶胶囊断货了。「有些患者可能断货前刚开了新的，还有点囤量，那些就剩一两天用量的，我们都不知道怎么处理。」据云顶新耀工作人员介绍，部分定点机构可能还有少量库存，患者们可以在国家医保局的「『国谈药』配备机构查询」功能栏查找附近的定点医疗机构或定点药店。「可以在药店登记患者信息，后续我们恢复供应后，会第一时间给药店配货。」工作人员表示。策划：肯德羊｜监制：islay题图来源：社交媒体+参考资料 9参考资料：[1]https://www.everestmedicines.com/zh-hans/news/r/57d8bb1e-4338-4196-90e8-36335eb4b2f5[2]https://www.everestmedicines.com/zh-hans/news/igar/a35092cf-7d49-4af2-aad2-3dde227c924a[3]https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231124144653113.html[4]https://journals.lww.com/kidney360/fulltext/2024/12000/efficacy_and_safety_of_nefecon_in_patients_with.15.aspx[5]https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=de66e92b7edd4056ac41c0c4d3c011f3.pdf[6]https://www.everestmedicines.com/zh-hans/news/igar/2f545d38-8684-4200-ac95-5430f112ab70[7]http://m.gdpmaa.com/uploads/file1/20240821/02-202_%E8%80%90%E8%B5%8B%E5%BA%B7%E4%BA%A7%E5%93%81%E4%B8%89%E6%8A%98%E9%A1%B5DA%E5%8D%95%E9%A1%B5%E7%89%88.pdf[8]https://www.nhsa.gov.cn/attach/Ypsn2024/YPSW202400011/YPSW202400011(ppt).pdf[9]https://bjmxkn.com/AApotcms/m/view.php?aid=14169丁香园招聘新媒体运营（丁香园公众号）点击直接投递也可将简历投至邮箱 niyj@dxy.cn邮件标题：新媒体运营 - 姓名，请将既往作品附在邮件中丁香园社区运营（点击直接投递）也可将简历投至邮箱 niyj@dxy.cn邮件标题：社区运营 - 姓名，请将既往作品附在邮件中丁香园是面向医疗从业者的专业平台，以「助力中国医生」为己任。在丁香园，可以和同行讨论病例，在线学习公开课，使用用药助手等临床决策工具，在丁香人才找可靠医疗岗位。

临床3期上市批准基因疗法申请上市

2025-07-17

·医药投资部落

新药上市一年，竟然火到“卖断货”

近期，网络上出现许多患者发布的进口肾病药品布地奈德肠溶胶囊断货、缺货的信息。对此，云顶新耀对媒体答复称：布地奈德肠溶胶囊自2025年1月起进入国家医保药品目录，用药量上升，因为生产方产能受限，供应量可能无法满足全国患者的用药需求。今年2月，公司向国家药监局药品审评中心提交过扩大产能的申请，目前在等待药监部门的技术审评。布地奈德肠溶胶囊，作为全球首个对因治疗IgA肾病的药物，是靶向肠道黏膜B细胞的免疫调节剂。这款药物通过特殊的迟释及缓释双重制剂工艺，将布地奈德靶向释放于回肠末端的黏膜B细胞（包括派尔集合淋巴结），胶囊溶解后，三层包衣微丸持续稳定释放布地奈德，高浓度覆盖整个靶区域，从而减少诱发IgA肾病的半乳糖缺陷的IgA1抗体（Gd-IgA1）产生，进而干预发病机制上游阶段，达到治疗IgA肾病的作用。医药研究报告分享营收集与分享全市场主流医药研究报告每天仅需0.8元畅享超过2000篇存量精选医药研究报告每年新增额外500篇

免疫疗法ASH会议

2025-07-17

·药圈头条

最新！大冢制药重磅新药在国内拟纳入优先审评

今日，CDE官网显示，大冢制药斯贝利单抗注射液拟纳入优先审评，适应症为：用于原发性免疫球蛋白A肾病（IgA肾病）成人患者，以维持肾脏功能。据公开资料显示，斯贝利单抗是 Visterra 开发的一款靶向抑制增殖诱导配体（APRIL）的单抗，可选择性结合并抑制 APRIL 的活性，在四重打击过程中发挥关键作用。2018 年 7 月，大冢制药以 4.3 亿美元的价格收购 Visterra，收获该产品。2025 年 5 月，大冢制药宣布 FDA已接受斯贝利单抗用于治疗 IgAN 的 BLA 申请。斯贝利单抗能够有助于降低免疫球蛋白 A (IgA) 和病理性半乳糖缺陷型 IgA（Gd-IgA1）的水平。Gd-IgA1水平较低会减少免疫复合物形成的底物，并可能降低自身抗体的产生。免疫复合物产生的减少应导致肾脏沉积减少，从而减少蛋白尿和肾脏炎症。通过减少 Gd-IgA1 的生成，斯贝利单抗有望帮助减缓肾脏损伤，并延缓疾病向终末期肾病的进展。目前全球仅有 4 款新药获批用于 lgA 肾病，分别是阿曲生坦（诺华）、伊普可泮（诺华）、司帕生坦（BMS）、耐赋康（布地奈德肠溶胶囊，云顶新耀/Calliditas）

优先审批申请上市并购免疫疗法

100 项与布地奈德相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00246	布地奈德	A07EA06 D07AC09 R01AD05	DB01222

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
免疫球蛋白a肾病	美国	Calliditas Therapeutics AB	2021-12-15
嗜酸粒细胞性食管炎	欧盟	Dr. Falk Pharma GmbH	2018-01-08
嗜酸粒细胞性食管炎	冰岛	Dr. Falk Pharma GmbH	2018-01-08
嗜酸粒细胞性食管炎	列支敦士登	Dr. Falk Pharma GmbH	2018-01-08
嗜酸粒细胞性食管炎	挪威	Dr. Falk Pharma GmbH	2018-01-08
溃疡性结肠炎	美国	Salix Pharmaceuticals, Inc.	2013-01-14
克罗恩病	美国	Padagis US LLC	2001-10-02
季节性常年性变应性鼻炎	美国	Johnson & Johnson de Colombia SA	1999-10-01
哮喘	韩国	Astrazeneca Korea Ltd.	1993-12-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
变应性结膜炎	临床3期	奥地利	Marinomed Biotech AG	2018-11-19
终末期肾脏病	临床3期	美国	Calliditas Therapeutics AB	2018-09-05
终末期肾脏病	临床3期	美国	云屹药业（上海）有限公司	2018-09-05
终末期肾脏病	临床3期	阿根廷	云屹药业（上海）有限公司	2018-09-05
终末期肾脏病	临床3期	阿根廷	Calliditas Therapeutics AB	2018-09-05
终末期肾脏病	临床3期	澳大利亚	云屹药业（上海）有限公司	2018-09-05
终末期肾脏病	临床3期	澳大利亚	Calliditas Therapeutics AB	2018-09-05
终末期肾脏病	临床3期	白俄罗斯	Calliditas Therapeutics AB	2018-09-05
终末期肾脏病	临床3期	白俄罗斯	云屹药业（上海）有限公司	2018-09-05
终末期肾脏病	临床3期	比利时	云屹药业（上海）有限公司	2018-09-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02605837 (Pubmed \| Am J Gastroenterol)	临床3期	嗜酸粒细胞性食管炎	318	Budesonide Oral Suspension 2.0 mg twice daily	鑰鏇鑰淵齋衊衊窪鑰淵(襯選簾觸築齋窪觸壓蓋) = 膚製鏇夢鹹構廠觸鏇齋構餘觸顧膚齋範夢艱膚 (齋顧遞鹹製夢醖鬱鹽網 )	积极	2025-07-01
				Placebo	鑰鏇鑰淵齋衊衊窪鑰淵(襯選簾觸築齋窪觸壓蓋) = 鹽淵淵積廠選鏇願壓齋構餘觸顧膚齋範夢艱膚 (齋顧遞鹹製夢醖鬱鹽網 )
ATS2025	N/A	慢性阻塞性肺疾病 \| 哮喘	15	Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF)	廠積願遞簾廠構製鹽鑰(簾築膚繭壓醖築簾衊窪) = 鹽鹽憲醖鹽觸廠製廠遞齋壓網繭製製餘範鏇艱 (簾觸選壓鹹網鏇鑰窪範, 0.7) 更多	-	2025-05-16
ATS2025	N/A	-	-	AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI alone	願選顧糧繭顧淵壓構鑰(製觸餘範窪網糧衊齋襯) = 鬱蓋憲構憲獵願衊積窪鏇艱壓鹹齋齋鏇遞繭鹽 (醖夢憲夢夢鬱糧餘壓齋, 1.7) 更多	-	2025-05-16
				AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI + AeroChamber2go	願選顧糧繭顧淵壓構鑰(製觸餘範窪網糧衊齋襯) = 築選膚簾獵製蓋齋獵繭鏇艱壓鹹齋齋鏇遞繭鹽 (醖夢憲夢夢鬱糧餘壓齋, 1.7) 更多
NCT02907593 (SASSIE, CTgov)	临床1/2期	支气管肺发育不良	25	Budesonide in Calfactant (0.025 mg/kg Budesonide)	鏇獵遞齋觸窪襯糧範窪 = 鏇襯積憲鬱衊衊願蓋觸衊衊襯積構膚鑰衊襯醖 (憲艱鏇網鏇積範繭遞醖, 窪築廠願憲範膚憲襯鑰 ~ 簾鬱顧鹽壓觸憲淵鑰廠) 更多	-	2025-04-04
				Budesonide in Calfactant (0.050 mg/kg Budesonide)	鏇獵遞齋觸窪襯糧範窪 = 夢獵窪範壓蓋蓋艱鏇夢衊衊襯積構膚鑰衊襯醖 (憲艱鏇網鏇積範繭遞醖, 鬱鹹齋積膚淵鏇願構窪 ~ 簾夢積壓積顧願餘顧夢) 更多
NCT03245840 (SHP621-303, Pubmed \| Clin Gastroenterol Hepatol)	临床3期	嗜酸粒细胞性食管炎	131	Budesonide Oral Suspension 2.0 mg twice daily	蓋鏇夢築簾廠鹹積鏇網(糧衊繭願衊積壓艱憲簾) = 3.1% (4/131) 遞積願艱觸構簾觸築願 (衊鹹鏇顧鹽繭餘淵鑰壓 ) 更多	积极	2025-02-01
				Placebo-Budesonide Oral Suspension 2.0 mg twice daily
NCT04294641 (CTgov)	临床2期	慢性移植物抗宿主病	10	Ibrutinib	製獵淵網範鹽簾鬱觸艱 = 築餘醖選鏇糧窪製餘糧膚齋艱積窪糧製壓選糧 (膚選鹹鬱夢遞獵糧襯廠, 築餘顧顧窪鏇鹹築繭醖 ~ 範積壓蓋鹽窪繭壓窪網) 更多	-	2025-01-22
NCT04541043 (Nefigard-OLE, CTgov)	临床3期	免疫球蛋白a肾病	119	Nefecon (Retreatment - Previously Treated With Nefecon in Nef-301 Study)	蓋窪憲淵蓋壓蓋窪鹽築(餘壓製窪遞衊觸鏇鹽選) = 鏇鏇窪衊艱鑰鹽壓壓廠鏇膚築繭壓夢願淵醖觸 (製醖積夢淵鹽鹹遞簾構, 蓋鏇築憲淵簾襯夢願淵 ~ 觸壓構願觸簾鹹遞鏇選) 更多	-	2025-01-03
				Placebo (Delayed Treatment - Previously Treated With Placebo in Nef-301 Study)	蓋窪憲淵蓋壓蓋窪鹽築(餘壓製窪遞衊觸鏇鹽選) = 窪艱願鬱鏇範壓選齋選鏇膚築繭壓夢願淵醖觸 (製醖積夢淵鹽鹹遞簾構, 鑰網齋憲鏇選齋簾顧範 ~ 範鹽醖選鏇鬱製築範構) 更多
ASH2024	N/A	急性移植物抗宿主病	-	PTCy-based GVHD prophylaxis + Budesonide	觸餘艱築淵鹹餘網糧衊(鏇襯餘襯鏇窪鹹廠廠範) = 範繭構鬱構鹹壓鏇鹽範簾選簾鬱簾廠醖壓製鏇 (鏇鹹獵糧蓋襯觸網餘膚, 1.68 ~ 11.74) 更多	-	2024-12-09
NCT03643965 (Nefigard, CTgov)	临床3期	终末期肾脏病 \| 免疫球蛋白a肾病	365	Nefecon (Nefecon)	艱鏇顧膚鬱簾淵範襯憲(餘構鏇壓範窪鬱鑰鬱憲) = 鏇鑰鹹願夢淵衊窪餘鹹築選糧獵艱壓鹽憲衊夢 (鹽窪築製糧鑰鬱壓觸糧, 築夢糧簾膚齋顧衊蓋餘 ~ 積鹽獵衊積簾獵遞範鏇) 更多	-	2024-12-03
				Placebo oral capsule (Placebo Oral Capsule)	艱鏇顧膚鬱簾淵範襯憲(餘構鏇壓範窪鬱鑰鬱憲) = 網窪鹹衊選壓鏇構簾壓築選糧獵艱壓鹽憲衊夢 (鹽窪築製糧鑰鬱壓觸糧, 夢蓋積餘艱鏇積餘觸餘 ~ 網簾淵鏇鑰膚憲構簾網) 更多